BioMarin Pharmaceutical Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $989.71Mn |
Net Profits | $44.76Mn |
Net Profit Margins | 4.52% |
BioMarin Pharmaceutical Inc. Common Stock’s revenue jumped 19.91% since last year same period to $989.71Mn in the Q2 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated 29.17% jump in its revenue since last 3-months.
BioMarin Pharmaceutical Inc. Common Stock’s net profit fell -81.39% since last year same period to $44.76Mn in the Q2 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated -57.58% fall in its net profits since last 3-months.
BioMarin Pharmaceutical Inc. Common Stock’s net profit margin fell -84.48% since last year same period to 4.52% in the Q2 2026. On a quarterly growth basis, BioMarin Pharmaceutical Inc. Common Stock has generated -67.16% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 1.14 |
EPS Estimate Current Year | 1.14 |
BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.14 - a 44.3% jump from last quarter’s estimates.
BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.14.
Key Ratios
Earning Per Share (EPS) | 0.9 |
BioMarin Pharmaceutical Inc. Common Stock’s earning per share (EPS) fell -37.5% since last year same period to 0.9 in the Q2 2026. This indicates that the BioMarin Pharmaceutical Inc. Common Stock has generated -37.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-05 | 0.91 | 0.76 | -16.48% |
2026-08-06 | 0.79 | 0.9 | 13.92% |
